- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00273325
Immunogenicity of PCV-7 Vaccine in VLBW Infants (PCV-7)
Observational Study of the Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Very-low-birth-weight Infants
Studienübersicht
Status
Detaillierte Beschreibung
Streptococcus pneumoniae causes an estimated 10-25% of all pneumonias in the United States, and is responsible for an estimated 40,000 deaths per year. Invasive pneumococcal disease has a peak incidence of 235/100,000 among children aged 6-11 months. Pneumococcal meningitis carries a higher risk of death (15%) or neurodevelopmental impairment (12-28%) than Hib or Neisseria meningitides.
Premature infants are at a higher risk for invasive disease with Streptococcus pneumoniae. The heptavalent pneumococcal-CRM197 conjugate vaccine (PCV-7) effectively prevents invasive pneumococcal disease in full-term infants, but was been incompletely studied in premature infants. The American Academy of Pediatrics (AAP) recommends that "prematurely born infants, including infants of low birth weight, should be immunized at the usual chronological age in most cases", but cautions that "some studies suggest a reduced immune response in very low-birth-weight infants (<1500 g)."
This observational study assessed the effectiveness of the PCV-7 vaccine to generate a sufficient immune response in a safe manner when given to very low birth weight (VLBW) infants in routine pediatric practice. We hypothesized that among VLBW infants, the frequency of estimated minimum protective antibody titers to PCV-7 (>=0.15 μg/mL) would decrease with decreasing birth weight.
Infants 501-1500g birth weight and <32 0/7 weeks gestational age were enrolled from nine NICHD Neonatal Research Network centers from 2004 to 2006. Enrollment was stratified by weight group to yield approximately 20 infants per 100g increments from 501-1500g birth weight whose primary PCV-7 series was initiated before 3 months and completed by 8 months after birth. The infants' primary providers gave PCV-7 vaccination at 2, 4, and 6 months after birth. Infants had a single 2-ml blood sample drawn 4-6 weeks following the third dose of PCV-7. Antibodies for each of the seven vaccine serotypes included in PCV-7 were measured by enzyme-linked immunosorbent assay. Children were followed until 18-22 months corrected age to assess survival, infection, and neurodevelopmental outcomes.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- University of Alabama at Birmingham
-
-
California
-
Palo Alto, California, Vereinigte Staaten, 94304
- Stanford University
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30303
- Emory University
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University
-
-
New York
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University
-
Durham, North Carolina, Vereinigte Staaten, 27705
- RTI International
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75235
- University of Texas Southwestern Medical Center at Dallas
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion criteria
- Gestational age <32 0/7 weeks
- Included in Neonatal Research Network Generic Database
- Family has a telephone at home
- Anticipated availability for blood draw 4-6 weeks following 3rd vaccine dose
- Consent obtained before first dose of PCV-7 is given
Exclusion criteria
- Known immunodeficiency
- HIV exposure
- Parental non-consent
- Primary care pediatrician not willing to participate
- Enrollment in a conflicting trial
- Infant has not received first dose of PCV-7 vaccine by 3 months of age
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Serotype 6B pneumococcal capsular polysaccharide antibody >=0.15 μg/ml
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Pneumococcal capsular polysaccharide antibody >=0.15 μg/ml for the other six vaccine serotypes
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Pneumococcal capsular polysaccharide antibodies >=1.0 μg/ml for all seven vaccine serotypes
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Geometric mean titers of pneumococcal capsular polysaccharide antibody to the seven vaccine serotypes
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Pneumococcal capsular polysaccharide antibodies >=0.15 μg/ml and >=1.0 μg/ml, and geometric mean titers of antibody, to the seven vaccine serotypes in children completing the primary series, regardless of postnatal age
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Opsonization of 6B pneumococcal capsular polysaccharide plus 1 low immunogenicity, high prevalence serotype (e.g., 23F) among infants in the lowest quartile of antibody response
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Effect of possible mediating variables on the achievement of levels of serotype 6B pneumococcal capsular polysaccharide antibody >=0.15 μg/ml
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Effect of pneumococcal conjugate immunization status (complete & timely v. complete v. incomplete) on outcome (survival, serious infection, neurodevelopmental outcome) at 18-22 months corrected age in infants <=1000g
Zeitfenster: 18-22 months corrected age
|
18-22 months corrected age
|
Levels of antibody >=0.15 μg/ml and >=1.0 μg/ml to Hib polyribosylribitol
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Avidity of antibody to Hib-PRP among infants in the lowest quartile of antibody response,regardless of postnatal or gestational age
Zeitfenster: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Shahnaz Duara, MD, University of Miami
- Hauptermittler: Carl T. D'Angio, MD, University of Rochester
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- D'Angio CT, Heyne RJ, O'Shea TM, Schelonka RL, Shankaran S, Duara S, Goldberg RN, Stoll BJ, Van Meurs KP, Vohr BR, Das A, Li L, Burton RL, Hastings B, Phelps DL, Sanchez PJ, Carlo WA, Stevenson DK, Higgins RD; NICHD Neonatal Research Network. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J. 2010 Jul;29(7):600-6. doi: 10.1097/INF.0b013e3181d264a6.
- Wynn JL, Li L, Cotten CM, Phelps DL, Shankaran S, Goldberg RN, Carlo WA, Van Meurs K, Das A, Vohr BR, Higgins RD, Stoll BJ, D'Angio CT. Blood stream infection is associated with altered heptavalent pneumococcal conjugate vaccine immune responses in very low birth weight infants. J Perinatol. 2013 Aug;33(8):613-8. doi: 10.1038/jp.2013.5. Epub 2013 Jan 31.
- Ang JY, Lua JL, Asmar BI, Shankaran S, Heyne RJ, Schelonka RL, Das A, Li L, Jackson DM, Higgins RD, D'Angio CT; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Nasopharyngeal carriage of Streptococcus pneumoniae in very low-birth-weight infants after administration of heptavalent pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med. 2010 Dec;164(12):1173-5. doi: 10.1001/archpediatrics.2010.233. No abstract available.
- D'Angio CT, Murray TE, Li L, Heyne RJ, O'Shea TM, Schelonka RL, Shankaran S, Duara S, Goldberg RN, Stoll BJ, Stevenson DK, Vohr BR, Phelps DL, Carlo WA, Pichichero ME, Das A, Higgins RD; NICHD Neonatal Research Network. Immunogenicity of Haemophilus influenzae type b protein conjugate vaccines in very low birth weight infants. Pediatr Infect Dis J. 2013 Dec;32(12):1400-2. doi: 10.1097/01.inf.0000437263.04493.7c. No abstract available.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Pneumokokken-Impfstoffe
- Immunogenität
- Frühgeburtlichkeit
- Impfstoffe, Konjugat
- Impfantwort
- NICHD Neonatal Research Network
- Sehr niedriges Geburtsgewicht (VLBW)
- Extrem niedriges Geburtsgewicht (ELBW)
- Heptavalent pneumococcal conjugate vaccine (PCV-7)
- pneumococcal polysaccharide, type 6B
- Pneumococcal polysaccharide, type 14
- Pneumococcal polysaccharide, type 19F,
- Pneumococcal polysaccharide, 23F
- Pneumococcal polysaccharide, 18C
- Pneumococcal polysaccharide, 4
- Pneumococcal polysaccharide, 9V
Zusätzliche relevante MeSH-Bedingungen
- Infektionen
- Infektionen der Atemwege
- Erkrankungen der Atemwege
- Lungenentzündung
- Lungenkrankheit
- Körpergewicht
- Bakterielle Infektionen
- Bakterielle Infektionen und Mykosen
- Streptokokken-Infektionen
- Grampositive bakterielle Infektionen
- Lungenentzündung, bakteriell
- Pneumokokken-Infektionen
- Lungenentzündung, Pneumokokken
- Geburtsgewicht
Andere Studien-ID-Nummern
- NICHD-NRN-0031
- M01RR000633 (US NIH Stipendium/Vertrag)
- UL1RR024982 (US NIH Stipendium/Vertrag)
- U10HD021385 (US NIH Stipendium/Vertrag)
- U10HD027851 (US NIH Stipendium/Vertrag)
- U10HD027880 (US NIH Stipendium/Vertrag)
- U10HD034216 (US NIH Stipendium/Vertrag)
- U10HD040492 (US NIH Stipendium/Vertrag)
- U10HD040689 (US NIH Stipendium/Vertrag)
- UL1RR025744 (US NIH Stipendium/Vertrag)
- M01RR000070 (US NIH Stipendium/Vertrag)
- U10HD021397 (US NIH Stipendium/Vertrag)
- U10HD040498 (US NIH Stipendium/Vertrag)
- U10HD040521 (US NIH Stipendium/Vertrag)
- M01RR000032 (US NIH Stipendium/Vertrag)
- M01RR000039 (US NIH Stipendium/Vertrag)
- M01RR000044 (US NIH Stipendium/Vertrag)
- M01RR007122 (US NIH Stipendium/Vertrag)
- M01RR016587 (US NIH Stipendium/Vertrag)
- UL1RR025777 (US NIH Stipendium/Vertrag)
- UL1RR025008 (US NIH Stipendium/Vertrag)
- M01RR000030 (US NIH Stipendium/Vertrag)
- U01HD036790 (US NIH Stipendium/Vertrag)
- UL1RR024160 (US NIH Stipendium/Vertrag)
- UL1RR024128 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Pneumokokken-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen